Calypso Medical Technologies, Inc. has announced that it will showcase Calypso 4D Localization System and implantable Beacon transponders at the American Urological Association’s Annual Meeting in Chicago. Urologists across the country have implanted thousands of patients with Beacon transponders in their effort to ensure state-of-the-art prostate cancer care. The company’s proprietary technology known as GPS for the Body, utilizes minute implanted transponders to provide precise, continuous real-time information on the location of the tumor during prostate external beam radiation therapy and for post-operative prostatic bed patients experiencing a recurrence of disease. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit surrounding healthy tissue. In contrast to other tumor targeting solutions, GPS for the Body technology provides continuous tumor position information, objectively and without additional ionizing radiation, thereby enabling optimization of the delivery of radiation to the tumor and minimization of misapplied radiation to normal tissue. In addition to use in the prostate, the Calypso System received FDA 510(k) clearance for use in the post-operative prostatic bed in May 2008. Extraprostatic disease will manifest itself in one-third of men after radical prostatectomy, per the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study. A long-term randomized clinical trial, conducted by Dr. Ian Thompson, lead author of the study and chairman of urology at the University of Texas Health Science Center, suggests that the addition of adjuvant radiotherapy within 18 weeks following radical prostatectomy in men with Stage III (pT3N0M0) prostate cancer significantly reduces the risk of PSA recurrence, metastasis, the need for hormonal therapy and significantly increases survival.